BioSpace News Archive

Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.

Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France.

LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors.

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m. U.S. Eastern Time.

Avid Bioservices, Inc. today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).

Q32 Bio Inc. today announced that the company is joining the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

Nyxoah announced that the Company submitted the fourth and final module of its Premarket Approval application for Genio to the U.S. Food and Drug Administration (FDA).

Samsung Bioepis Co., Ltd. announced that the U.S. Food and Drug Administration has approved the Biologics License Application for PYZCHIVA® subcutaneous injection and intravenous infusion as a biosimilar to Stelara.

TauRx Pharmaceuticals Ltd has announced the submission of a UK Marketing Authorisation Application for hydromethylthionine mesylate for treatment of mild cognitive impairment and mild to moderate stages of dementia due to Alzheimer’s disease.